{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Cocrystal Pharma, Inc.
Is Cocrystal Pharma, Inc. overvalued or undervalued?
As of August 16, 2021, Cocrystal Pharma, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial performance and ratios, including a Price to Book Value of 2.27 and a year-to-date return of -22.28%, significantly underperforming compared to its peers and the S&P 500.
Is Cocrystal Pharma, Inc. technically bullish or bearish?
As of May 23, 2025, the trend is mildly bearish, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, reflecting mixed signals and a lack of strong momentum.
Who are in the management team of Cocrystal Pharma, Inc.?
As of March 2022, the management team of Cocrystal Pharma, Inc. includes Dr. Gary Wilcox as Chairman and CEO, with Dr. Roger Kornberg, Dr. Phillip Frost, Dr. Anthony Japour, and Mr. Steven Rubin serving as directors.
What does Cocrystal Pharma, Inc. do?
Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on developing antiviral therapeutics for serious viral diseases, with a market cap of $16.18 million and recent quarterly net profit of -$2 million.
How big is Cocrystal Pharma, Inc.?
As of Jun 18, Cocrystal Pharma, Inc. has a market capitalization of 16.18 million and reported net sales of 0.00 million with a net profit of -15.85 million over the last four quarters. Shareholder's funds are 9.52 million, and total assets amount to 13.46 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
